Post-translational modifications (PTMs)—including phosphorylation, acetylation, and ubiquitination—are specific modifications that can alter the activity of an individual protein target. The cumulative effect of these small modifications is the regulation of large signaling pathways and networks within cells.
Mass spectrometry is a powerful tool for the identification of individual PTMs during the investigation of signaling networks. A new approach using antibody-based peptide enrichment for a class of PTMs combined with tandem mass spectrometry has been successfully used for global identification of hundreds to thousands of PTMs within a sample. In this webinar, examples of how the technology was applied to each of these PTM classes will be described.
During this webinar, viewers will:
- Learn about post-translational modifications and their role in cellular signaling
- Discover how antibody-based proteomics approaches can be applied to identify, study, and characterize known and novel modifications
- Hear specific examples of how these approaches are being applied to the dissection of cellular signaling pathways, target identification, validation, and biomarker discovery by industry and academic experts
- Ask our expert panel questions in real time, during the broadcast
Vipin Suri, Ph.D.
Dr. Suri is currently director and head of pharmacology at Sirtris, a division of GlaxoSmithKline in Cambridge, Massachusetts. He obtained his Ph.D. in biochemistry at Brandeis University before joining the Metabolic Diseases Research Unit at Pfizer (formerly Wyeth), where, during his nine-year tenure, he focused on novel small molecule, peptide, nucleic acid, and protein therapeutics for obesity, type 2 diabetes, and other metabolic disorders. He moved to Sirtris in April 2010 and his research there is focused on the Sirtuin family of protein deacetylases, specifically understanding the regulation of protein acetylation and the role of Sirtuins in metabolic, inflammatory, and neurodegenerative diseases as well as the discovery of novel Sirtuin modulators as therapeutics for these diseases.
Cloud Paweletz, Ph.D.
Dana-Farber Cancer Institute
Dr. Paweletz is head of the Translational Research Laboratory (TRL) of the Belfer Institute for Applied Cancer Science in Cambridge, Massachusetts. He joined the Belfer Institute from Merck & Co., Inc., where he most recently served as principle scientist, externalization lead, and proteomics site lead for the Department of Molecular Biomarkers at the Merck Research Laboratory in Boston. At Merck, Dr. Paweletz successfully built platforms to look at disease biomarkers in body fluids and oversaw research activities spanning the spectrum from early-stage discovery to the clinic. Prior to that, he was a postdoctoral fellow in the Department of Physiology at the Uniformed Services University School of Medicine in Bethesda, Maryland and a research fellow in the Laboratory of Pathology at the National Cancer Institute, National Institutes of Health (NIH). Dr. Paweletz has received multiple awards and honors throughout his career, including a Fellows Award for Research Excellence and a Cancer Research Training Award from the NIH. Dr. Paweletz holds a Ph.D. and an M.S. in chemistry from Georgetown University in Washington, DC and a B.S. in chemistry from Baldwin Wallace College. Dr. Paweletz was recently part of a team that is helping to drive the development of mass spectrometric-based diagnosis and protein microarray-based disease detection.
Chunaram Choudhary, Ph.D.
University of Copenhagen
Dr. Choudhary is currently an associate professor and group leader at the NNF Center for Protein Research at the University of Copenhagen in Denmark. He carried out his doctoral studies at the University of Münster in Germany and his postdoctoral training at the same university as well as at the Max Planck Institute for Biochemistry in Martinsried, Germany (under Prof. Dr. Matthias Mann). Dr. Choudhary has been widely published in many reputable, peer-reviewed journals and in 2012, was awarded a prestigious Sapere Aude research grant from the Danish Research Council. His laboratory is interested in investigating the dynamics of protein posttranslational modifications in cell signaling networks using quantitative mass spectrometry-based approaches.
Moderator: Sean Sanders, Ph.D.
Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Editor for Custom Publishing for the journal Science and Program Director for Outreach.
For related product or technology information, go to: www.cellsignal.com/cstwebinar